Advertisement

Complement pp 379-406 | Cite as

Relationships Among the Complement, Kinin, Coagulation, and Fibrinolytic Systems

  • John S. Sundsmo
  • Daryl S. Fair

Abstract

The activities of the plasma proteins have been elucidated in studies with isolated constituents, and this has to a certain extent biased our concepts by compartmentalizing proteins into particular functional systems. Blood is a highly complex mixture of cells, proteins, and lipoproteins responsible for maintaining homeostasis. The possibility that proteins of the complement, coagulation, and fibrinolytic systems may interact in blood was recognized over a decade ago. Studies of the Shwartzman reaction induced by endotoxin revealed a relationship between the complement protein C3, fibrinogen, and platelets. Other studies showed that streptokinase and urokinase induce complement activation in blood through Cl. C3 was also implicated in coagulant mechanisms induced in blood by antigen-antibody complexes. The outgrowth of these now classical investigations has been the recent recognition that thrombin, kallikrein, and plasmin can cleave complement proteins, and that complement protease Factor B may act in a reciprocal manner to cleave prothrombin and plasminogen. The possible interactions between the proteins of the complement, coagulation, kinin, and fibrinolytic systems are numerous and few have been investigated in any detail. In a few cases purified proteins have been employed and the molar concentrations of enzyme required to cleave a substrate in an opposing system seem to be exceedingly large.

Keywords

Human Platelet Fibrinolytic System Human Complement Tissue Factor Activity Rabbit Platelet 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Accini L, Dixon FJ (1979) Degenerative vascular disease and myocardial infarction in mice with lupus-like syndrome. Am J Pathol 96: 477Google Scholar
  2. 2.
    Aoki N, von Kaulla KN (1969) Inactivation of human serum plasminogen antiactivator by synthetic fibrinolysis inducers. Thromb Diath Haemorrh 22: 251PubMedGoogle Scholar
  3. 3.
    Arroyave CM, Müller-Eberhard HJ (1973) Interactions between human C5, C6, and C7 and their functional significance in complement-dependent cytolysis. J Immunol 111: 536PubMedGoogle Scholar
  4. 4.
    Astrup T, Rosa AT (1974) A plasminogen proactivator-activator system in human blood effective in the absence of Hageman factor. Thromb Res 4: 609PubMedGoogle Scholar
  5. 5.
    Becker EL, Henson PM (1973) In vitro studies of immunologically induced secretion of mediators from cells and related phenomena. Adv Immunol 17: 93PubMedGoogle Scholar
  6. 6.
    Becker EL, Showell HJ, Henson PM, Hsu LS (1974) The ability of chemotactic factors to induce lysosomal enzyme release. I. The characteristics of the release, importance of surfaces, and the relation of enzyme release to chemotactic responsiveness. J Immunol 122: 2077Google Scholar
  7. 7.
    Becker S, Meuer S, Hadding U, Bitter-Suermann D (1978) Platelet activation: A new biological activity of guinea pig C3a-anaphylatoxin. Scand J Immunol 7: 173PubMedGoogle Scholar
  8. 8.
    Becker S, Hadding U, Schorlemmer HU, Bitter-Suermann D (1978) Demonstration of high-affinity binding sites for C3a-anaphylatoxin on guinea pig platelets. Scand J Immunol 8: 551PubMedGoogle Scholar
  9. 9.
    Beller FK, Mitchell P (1965) Production of the generalized Shwartzman reaction by protease inhibitors. Fed Proc 24: 155Google Scholar
  10. 10.
    Bianco C, Eden A, Cohn ZA (1976) The induction of macrophage spreading: Role of coagulation factors and the complement system. J Exp Med 144: 1531PubMedGoogle Scholar
  11. 11.
    Binder BR, Spragg J, Austen KF (1979) Purification and characterization of human vascular plasminogen activator derived from blood vessel perfusates. J Biol Chem 254: 1998PubMedGoogle Scholar
  12. 12.
    Bokisch VA, Müller-Eberhard HJ, Cochrane CG (1969) Isolation of a fragment ( C3a) of the third component of human complement containing anaphylatoxin activity and description of an anaphylatoxin inactivator of human serum. J Exp Med 129: 1109PubMedGoogle Scholar
  13. 13.
    Campbell WD, Nelson RA (1973) Thrombin and complement: Lack of reactivity of purified bovine and human thrombin on components of the complement system. Immunol Commun 2: 473PubMedGoogle Scholar
  14. 14.
    Cezenave J-P, Assimeh SN, Painter RH, Packham MA, Mustard JF (1976) Clq inhibition of the interaction of collagen with human platelets. J Immunol 116: 162Google Scholar
  15. 15.
    Cheng CM, Hawiger J (1979) Affinity isolation and characterization of immunoglobulin G Fc fragment binding glycoprotein from human blood platelets. J Biol Chem 254: 2165PubMedGoogle Scholar
  16. 16.
    Chmielewska J, Poggi A, Janik P, Latallo ZS, Donati MB (1980) Effect of defibrination with batroxobin on growth and metastasis of JW sarcoma in mice. Eur J Cancer 16: 919PubMedGoogle Scholar
  17. 17.
    Cines DB, Schreiber AD (1979) Immune thrombocytopenia: Use of Coombs antiglobulin test to detect IgG and C3 on platelets. N Engl J Med 300: 106PubMedGoogle Scholar
  18. 18.
    Coleman RW (1969) Activation of plasminogen by human plasma kallikrein. Biochem Biophys Res Commun 35: 273Google Scholar
  19. 19.
    Collen D (1980) On the regulation and control of fibrinolysis. Thromb Haemost 43: 77PubMedGoogle Scholar
  20. 20.
    Collen D (1980) Inhibitors of fibrinolysis. In: Kline DL, Reddy KNN (eds) Fibrinolysis. CRC Press, Boca Raton, Florida, p 129Google Scholar
  21. 21.
    Colten HR, Ooi YM, Edelson Pt (1979) Synthesis and secretion of complement proteins by macrophages. Ann NY Acad Sci 332: 482PubMedGoogle Scholar
  22. 22.
    Colten HR, Alper CA, Rosen FS (1981) Genetics and biosynthesis of complement proteins. N Engl J Med 304: 653PubMedGoogle Scholar
  23. 23.
    Colvin RB, Dvorak HF (1975) Role of the clotting system in cell-mediated hypersensitivity. II. Kinetics of fibrinogen/fibrin accumulation and vascular permeability changes in tuberculin and cutaneous basophil hypersensitivity reactions. J Immunol 114: 1377Google Scholar
  24. 24.
    Colvin RB, Mosesson MW, Dvorak HF (1979) Delayed-type hypersensitivity skin reactions in congenital afibrinogenemia lack fibrin deposition and induration. J Clin Invest 63: 1302PubMedGoogle Scholar
  25. 25.
    Condie RM, Hong CV, Good RA (1957) Reversal of the lesion of the generalized Shwartzman phenomenon by treatment of rabbits with streptokinase. J Lab Clin Med 50: 803Google Scholar
  26. 26.
    Cooper NR, Miles LA, Griffin JH (1979) Activation of purified Cl, the first component of complement by purified plasma kallikrein and plasmin. Thromb Haemost 42: 251Google Scholar
  27. 27.
    Cooper NR, Miles LA, Griffin JH (1980) Effects of plasma kallikrein and plasmin on the first complement component. J Immunol 124: 1517Google Scholar
  28. 28.
    Cooper NR, Miles LA, Griffin JH (to be published) Cleavage and activation of the first complement component by plasmin.Google Scholar
  29. 29.
    Corrigan JJ, Abilgaard CF, Vanderheiden JF, Schulman I (1967) Quantitative aspects of blood coagulation in the generalized Shwartzman reaction. Pediatr Res 1: 39Google Scholar
  30. 30.
    Cronlund M, Hardin J, Burton J, Lee L, Haber E, Bloch KJ (1976) Fibrinopeptide A in plasma of normal subjects and patients with disseminated intravascular coagulation and systemic lupus erythematosus. J Clin Invest 58: 142PubMedGoogle Scholar
  31. 31.
    Curman B, Sandberg-Tragardh L, Peterson PA (1977) Chemical characterization of human Factor B of the alternative pathway of complement activation. Biochemistry 16: 5368PubMedGoogle Scholar
  32. 32.
    Curry MJ, Morrison DC (1979) Role of complement in endotoxin-mediated lethality in mice. Immunopharmacology 1: 125PubMedGoogle Scholar
  33. 33.
    Dahlback B, Stenflo J (1981) High molecular weight complex in human plasma between vitamin K-dependent Protein S and complement component C4b-binding protein. Proc Natl Acad Sci USA 78: 2512PubMedGoogle Scholar
  34. 34.
    Davidson JF, Nilsson JM, Astedt B Eds (1981) In: Progress in Fibrinolysis, Vol. 5. Churchill Livingstone, EdinburghGoogle Scholar
  35. 35.
    Davie EW, Hanahan DJ (1977) Blood coagulation proteins. In: Putnam FW (ed) The plasma proteins, Vol. 3. Academic Press, New York, p 421Google Scholar
  36. 36.
    Dierich MP, Wilhelmi D, Till G (1977) Essential role of surface-bound chemoattractant in leukocyte migration. Nature 270: 351PubMedGoogle Scholar
  37. 37.
    DiScipio RG (1982) The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology 45: 587PubMedGoogle Scholar
  38. 38.
    Donaldson VH (1968) Mechanisms of activation of C’l esterase in hereditary angioneurotic edema plasma in vitro. J Exp Med 127: 411PubMedGoogle Scholar
  39. 39.
    Donaldson VH, Evans RR (1963) A biochemical abnormality in hereditary angioneurotic edema. Absence of serum inhibitor of C1-esterase. Am J Med 35: 37PubMedGoogle Scholar
  40. 40.
    Edgington TS, Levy GA, Schwartz BS, Fair DS (1981) A unidirectional pathway of lymphocyte-instructed macrophage and monocyte function characterized by the generation of procoagulant monokines. In: Weigle WO, Advances in immunopathology. Elsevier/North Holland, New York, p 173Google Scholar
  41. 41.
    Edwards RL, Rickles FR (1980) The role of monocyte tissue factor in the immune response. Lymphokine Reports 1: 181Google Scholar
  42. 42.
    Edwards RL, Rickles FR (1980) The role of human T cells and T cells products for monocyte tissue factor generation. J Immunol 125: 606PubMedGoogle Scholar
  43. 43.
    Edwards RL, Rickles FR, Bobrove AM (1979) Mononuclear cell tissue factor: Cell of origin and requirements for activation. Blood 54: 359PubMedGoogle Scholar
  44. 44.
    Fair D, Tsao B, Curtiss L, Edgington T (1983) Monocytes can be induced by lipopolysaccharide stimulated T cells to express Factor VII activity. Thromb Haemost 50: 172Google Scholar
  45. 45.
    Fair DS, Sundsmo JS, Schwartz BS, Edgington TS, Müller-Eberhard HJ (1981) Prothrombin activation by Factor B ( Bb) of the alternative pathway of complement. Thromb Haemost 46: 301Google Scholar
  46. 46.
    Fearon DT, Austen KF (1980) The alternative pathway of complement—A system for host resistance to microbial infection. N Engl J Med 303: 259PubMedGoogle Scholar
  47. 47.
    Fey G, Colten HR (1981) The biosynthesis of complement proteins. Fed Proc 40: 2099PubMedGoogle Scholar
  48. 48.
    Fiedel BA, Gewurtz H (1980) Complement ( Clq), polyanions and platelet activation. Thromb Res 19: 729PubMedGoogle Scholar
  49. 49.
    Forbes CD, Pensky J, Ratnoff OD (1970) Inhibition of activated Hageman factor and activated thromboplastin antecedent by purified Cl inactivator. J Lab Clin Med 76: 809PubMedGoogle Scholar
  50. 50.
    Fruton JS (1975) The specificity of proteinases toward protein substrates. In: Reich E, Rifkin DB, Shaw E Proteases and biological control. Cold Spring Harbor Laboratory, New York, p 33Google Scholar
  51. 51.
    Ghebrehewet B, Silverberg M, Kaplan AP (1981) Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med 153: 665Google Scholar
  52. 52.
    Gigli I, Mason JW, Colman RW, Austen KF (1970) Interactions of plasma kallikrein with Cl inhibitor. J Immunol 104: 574PubMedGoogle Scholar
  53. 53.
    Glovsky, MM, Hugh TE, Hartmann CT, Ghekiere L (1976) Possible role of C3a in human disease. In: Opferkuch W, Rother K, Schutz DR (eds) Clinical aspects of the complement system. George Thieme, Stuttgart, p 138Google Scholar
  54. 54.
    Goldstein IM, Perez HD (1980) Biologically active peptide derived from the fifth component of complement. Prog Hemost Thromb 5: 41PubMedGoogle Scholar
  55. 55.
    Gordon JL ed (1981) Platelets in biology and pathology 2. Elsevier/North Holland, New YorkGoogle Scholar
  56. 56.
    Graff KS, Leddy JP, Breckenridge RT (1976) Platelet function in man, a requirement for C5. J Immunol 116: 1735Google Scholar
  57. 57.
    Gramse M, Bingenheimer C, Schmidt W (1978) Degradation products of fibrinogen by elastase-like neutral protease from human granulocytes. Characterization and effects on blood coagulation in vitro. J Clin Invest 61: 1027PubMedGoogle Scholar
  58. 58.
    Halbwachs L, Lachmann PJ (1976) Factor B of the alternative complement pathway on human lymphocytes. Scand J Immunol 5: 697PubMedGoogle Scholar
  59. 59.
    Harpel PC (1970) Cl inactivator inhibition by plasmin. J Clin Invest 49: 568PubMedGoogle Scholar
  60. 60.
    Harpel PC (1970) Human plasma a-2-macroglobulin. An inhibitor of plasma kallikrein. J Exp Med 132: 329PubMedGoogle Scholar
  61. 61.
    Hathaway WE, Alsever J (1970) The relation of `Fletcher factor’ to Factors XI and XII. Br J Haematol 18: 161PubMedGoogle Scholar
  62. 62.
    Henson PM (1969) Role of complement and leukocytes in immunologic release of vasoactive amines from platelets. Fed Proc 28: 1721PubMedGoogle Scholar
  63. 63.
    Henson PM (1970) Mechanisms of release of constituents from rabbit platelets by antigen-antibody complexes and complement. I. Lytic and non-lytic reactions. J Immunol 105: 476PubMedGoogle Scholar
  64. 64.
    Henson PM, Betz SJ (1980) In: Kelly WN, Harris ED, Ruddy, S, Sledge G. B. (eds) A textbook of rheumatology. Saunders Philadelphia, p 72Google Scholar
  65. 65.
    Henson PM, Ginsberg MH (1981) Immunological reactions of platelets. In: Gordon GL (ed) Platelets in biology and pathology 2. Elsevier/North Holland, New York, p 265Google Scholar
  66. 66.
    Henson PM, Pinckard RN (1977) Platelet-activating factor (PAF). A possible direct mediator of anaphylaxis in rabbits and a trigger for the vascular deposition of circulating immune complexes. Monogr Allergy 12: 13PubMedGoogle Scholar
  67. 67.
    Henson PM Spiegelberg HL (1973) Release of serotonin from human platelets induced by aggregated immunoglobulins of different classes and subclasses. J Clin Invest 52: 1282PubMedGoogle Scholar
  68. 68.
    Henson PM, McCarthy K, Larsen GL, Webster RO, Giclas PC, Dreisin RB, King TE, Shaw JO (1979) Complement fragments, alveolar macrophages and alveolitis. Am J Pathol 97: 93PubMedGoogle Scholar
  69. 69.
    Henson PM, Hollister JR, Musson RA, Webster RO, Spears P, Henson JE, McCarthy KM (1979) Inflammation as a surface phenomenon: Initiation of inflammatory processes by surface-bound immunologic components. Adv Inflam Res 1: 341Google Scholar
  70. 70.
    Heusinkveld RS, Leddy JP, Klemperer MR, Breckenridge RT (1974) Hereditary deficiency of the sixth component of complement in man. II. Studies of hemostasis. J Clin Invest 53: 554PubMedGoogle Scholar
  71. 71.
    Horowitz HI, Des Prez RM, Hook EW (1962) Effects of bacterial endotoxin on rabbit platelets. II. Enhancement of platelet factor 3 activity in vitro and in vivo. J Exp Med 116: 619PubMedGoogle Scholar
  72. 72.
    Hoylaertx M, Rijken DC, Cohen D (1982) Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 257: 2912Google Scholar
  73. 73.
    Hugh TE (1977) Complement factors and inflammation: Effects of thrombin on components of C3 and C5. In: Lundblad RL, Fenton JW, Mann KG (eds). Chemistry and biology of thrombin. Ann Arbor Science Publishers, Michigan, p 345Google Scholar
  74. 74.
    Hugh TE (1981) The structural basis for anaphylatoxin and chemotactic functions of C3a, C4a, and CSa. CRC Crit Rev Immunol 1: 321Google Scholar
  75. 75.
    Hugh TE (1981) Interrelationships between coagulation and complement activation. In: Fareed J, Messmore HL, Fenton JW, Brinkhous KM (eds) Perspectively in hemostasis. Pergamon Press, New York, p. 59Google Scholar
  76. 76.
    Jackson CM, Nemérson Y (1980) Blood coagulation. Annu Rev Biochem 49: 765PubMedGoogle Scholar
  77. 77.
    Jacob HS (1980) Complement-induced vascular leukostasis. Its role in tissue injury. Arch Pathol Lab Med 104: 617PubMedGoogle Scholar
  78. 78.
    Johnson U, Ohlsson K, Olsson I (1976) Effects of granulocyte neutral proteases on complement components. Scand J Immunol 5: 421PubMedGoogle Scholar
  79. 79.
    Kagan LJ, Leddy JP, Becker EL (1963) The presence of two permeability globulins in human serum. J Clin Invest 42: 1353Google Scholar
  80. 80.
    Kanyerezi B, Lwanga AK, Block KJ (1971) Fibrinogen degradation products in serum and urine of patients with systemic lupus erythematosus. Relation to renal disease and pathogenetic mechanisms. Arthritis Rheum 14: 267PubMedGoogle Scholar
  81. 81.
    Kaplan AP, Austen KF (1971) A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med 133: 696PubMedGoogle Scholar
  82. 82.
    Kaplan AP, Austen KF (1972) The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator. J Exp Med 136: 1378PubMedGoogle Scholar
  83. 83.
    Kaplan AP, Goetzl EJ, Austen KF (1973) The fibrinolytic pathway of human plasma. II. The generation of chemotactic activity by activation of plasminogen proactivator. J Clin Invest 52: 2591PubMedGoogle Scholar
  84. 84.
    Kernbaum S, Bastin R, Wautier J-L, Bure A, Gougerot M, Peltier AP (1980) Human deficiency of the sixth component of complement in a patient with meningoccal meningitis and no haemostasis abnormality. Biomedicine 33: 197PubMedGoogle Scholar
  85. 85.
    Kleinmaier H, Goergen K, Lasch HG, Krecke HJ, Bohle A (1959) Studies on the problem of blood coagulation disorder in Sanarelli-Shwartzman phenomenon (so called generalized Shwartzman phenomenon of the rabbit). Z Ges Exptl Med 132: 275Google Scholar
  86. 86.
    Klinman A, McKay DG (1958) The prevention of the generalized Shwartzman reaction by fibrinolytic activity. Arch Pathol Lab Med 66: 715Google Scholar
  87. 87.
    Kondo M, Hosokawa K, Masuda M (1976) Cold activation of complement. I. Presence of coagulation-related activator. J Immunol 117: 486PubMedGoogle Scholar
  88. 88.
    Lachmann PJ, Thompson RA (1970) Reactive lysis: The complement mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification an C7. J Exp Med 131: 643PubMedGoogle Scholar
  89. 89.
    Lachmann PJ, Kay AB, Thompson R (1970) The chemotactic activity for neutrophil and eosinophil leucocytes of the trimolecular complex of the fifth, sixth, and seventh components of human complement (C5, 6, 7) prepared in free solution by the `reactive lysis’ procedure. Immunology 19: 895PubMedGoogle Scholar
  90. 90.
    Landerman NS, Webster ME, Becker EL, Ratcliff HE (1962) Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J Allergy 33: 330PubMedGoogle Scholar
  91. 91.
    Lesavre PH, Müller-Eberhard HJ (1978) Mechanism of action of Factor D of the alternative complement pathway. J Exp Med 148: 1498PubMedGoogle Scholar
  92. 92.
    Laurell A-B, Lundh B, Malinquist J (1965) Inability of highly purified streptokinase preparations to inactivate complement in serum. Acta Microbiol Scand 64: 318Google Scholar
  93. 93.
    Lepow IH, Wurz L, Ratnoff OD, Pillemer L (1954) Studies on the mechanisms of inactivation of human complement by plasmin and by antigen-antibody aggregates. J Immunol 73: 146PubMedGoogle Scholar
  94. 94.
    Lepow IH, Ratnoff OD, Levy LR (1958) Studies on the activation of a proesterase associated with partially purified first component of complement. J Immunol 107: 451Google Scholar
  95. 95.
    Lerner RG, Rapaport SI, Siemsen JK, Spitzer JM (1968) Disappearance of fibrinogen-’31I after endotoxin: effects of a first and second injection. Am J Physiol 214: 532PubMedGoogle Scholar
  96. 96.
    Lerner RG, Goldstein R, Cummings G (1971) Stimulation of human leukocyte thromboplastic activity by endotoxin. Proc Soc Exp Biol Med 138: 145PubMedGoogle Scholar
  97. 97.
    Levin J, Beck E (1966) A reappraisal of the role of blood coagulation and platelets in the generalized Shwartzman phenomenon. Thromb Diath Haemorrh 15: 519PubMedGoogle Scholar
  98. 98.
    Levy GA, Edgington TS (1980) Lymphocyte cooperation is required for amplification of macrophage procoagulant activity. J Exp Med 151: 1232PubMedGoogle Scholar
  99. 99.
    Levy GA, Schwartz BS, Edgington TS (1981) The kinetics and metabolic requirements for direct lymphocyte induction of human procoagulant monokines by bacterial lipopolysaccharide. J Immunol 127: 357PubMedGoogle Scholar
  100. 100.
    Levy GA, Leibowitz JL, Edgington TS (1981) Induction of monocyte procoagulant activity by murine hepatitis virus type 3 parallels disease susceptibility in mice. J Exp Med 154: 1150PubMedGoogle Scholar
  101. 101.
    Levy GA, Schwartz BS, Curtiss LK, Edgington TS (1981) Plasma lipoprotein induction and suppression of the generation of cellular procoagulant activity in vitro. Requirements for cellular cooperation. J Clin Invest 67: 1614PubMedGoogle Scholar
  102. 102.
    Maillard JL, Favreau C (1981) Plasminogen activation by normal B lymphocytes, a function associated with the cell membrane. J Immunol 126: 1126PubMedGoogle Scholar
  103. 103.
    Mandle RJ, Kaplan AP (1977) Hageman factor substrates. Human plasma kallikrein: Mechanism of activation of Hageman factor and participation in Hageman factor-dependent fibrinolysis. J Biol Chem 252: 6097PubMedGoogle Scholar
  104. 104.
    Martin SE, Breckenridge RT, Rosenfeld SI, Leddy JP (1978) Responses of human platelets to immunologic stimuli: Independent roles for complement and IgG in zymosan activation. J Immunol 120: 9PubMedGoogle Scholar
  105. 105.
    Marx JL (1982) Coagulation as a common thread in disease. Science 218: 145PubMedGoogle Scholar
  106. 106.
    Mason RG, Saba HI (1978) Normal and abnormal hemostasis—An integrated view. Am J Pathol 92: 775PubMedGoogle Scholar
  107. 107.
    McKay DG, Shapiro SS, Shanberge JN (1958) Alterations in the blood coagulation system induced by bacterial endotoxins. I. In vivo generalized Shwartzman reaction J Exp Med 107: 353PubMedGoogle Scholar
  108. 108.
    McKay DG, Shapiro SS, Shanberge JN (1958) Alterations in the blood coagulation system induced by bacterial endotoxins. II. In vitro. J Exp Med 107: 369PubMedGoogle Scholar
  109. 109.
    McManus LM, Hanahan DJ, Demopoulas CA, Pinckard RN (1980) Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor ( PAF), in the rabbit. J Immunol 124: 2914Google Scholar
  110. 110.
    Menzel EJ, Smolen JS, Liotta L, Reid KBM (1981) Interaction of fibronectin with Clq and its collagen-like fragment ( CLF ). FEBS Lett 129: 188PubMedGoogle Scholar
  111. 111.
    Meuer S, Hugh TE, Andreatta RH, Hadding U, Bitter-Suermann, D (1981) Comparative study on biological acitivities of various anaphylatoxins (C4a, C3a, C5a). Investigations on their ability to induce platelet secretion. Inflammation 5: 275Google Scholar
  112. 112.
    Meuer S, Ecker U, Hadding U, Bitter-Suermann D (1981) Platelet serotonin release by C3a and C5a: Two independent pathways of activation. J Immunol 126: 1506PubMedGoogle Scholar
  113. 113.
    Meuth JL, Morgan EL, Hugli TE (1983) Inhibition of human T cell blastogenesis by a kallikrein cleavage fragment of human iC3b. Fed Proc 42: 566Google Scholar
  114. 114.
    Morrison DC, Cochrane CG (1974) Direct evidence for Hageman factor ( Factor XII) activation by bacterial lipopolysaccharide. J Exp Med 140: 797PubMedGoogle Scholar
  115. 115.
    Morrison DC, Ulevitch RJ (1978) The effects of bacterial endotoxins on host mediation systems. Am J Pathol 93: 527Google Scholar
  116. 116.
    Morrison DC, Kline LF, Oades ZG, Henson PM (1978) Mechanisms of lipopolysaccharideinduced rabbit platelet responses: Alternative complement pathway dependence of the lytic response. Infect Immun 20: 744PubMedGoogle Scholar
  117. 117.
    Movat HZ, Mustard JF, Taichman NS, Uriuhara T (1965) Platelet aggregation and release of ADP, serotonin, and histamine associated with phagocytosis of antigen antibody complexes. Proc Soc Exp Biol Med 120: 232PubMedGoogle Scholar
  118. 118.
    Muhlfelder TW, Niemetz J, Kreutzer D, Beebe D, Ward PA, Rosenfeld SI (1979) C5 chemotactic fragment induces leukocyte production of tissue factor activity. A link between complement and coagulation. J Clin Invest 63: 147PubMedGoogle Scholar
  119. 119.
    Müller-Eberhard HJ (1975) Complement. Annu Rev Biochem 44: 697Google Scholar
  120. 120.
    Mustard JF, Packham MA (1970) Factors influencing platelet function: Adhesion, release and aggregation. Pharmacol Rev 22: 97PubMedGoogle Scholar
  121. 121.
    Nagaki K, Fujikawa K, Inai S (1965) Studies of the fourth component of complement. II. The fourth component of complement in guinea pig and human platelets. Biken J 8: 129Google Scholar
  122. 122.
    Nelson LA, Rosenfeld SL, Leddy JP (1980) Properties of immune complexes mediating aggregation of human platelets. Arthritis Rheum 23: 725aGoogle Scholar
  123. 123.
    Nemerson Y, Furie B (1980) Zymogens and cofactors of blood coagulation. CRC Crit Rev Biochem 9: 45PubMedGoogle Scholar
  124. 124.
    Nesheim ME, Katzmann JA, Tracy PB, Mann KG (1981) Factor V. Methods Enzymol 80: 249Google Scholar
  125. 125.
    Niemetz J (1972) Coagulant activity of leukocytes. Tissue factor activity. J Clin Invest 51: 307PubMedGoogle Scholar
  126. 126.
    Niemetz J, Fani K (1971) Role of leukocytes in blood coagulation and the generalized Shwartzman reaction. Nature 232: 247Google Scholar
  127. 127.
    Oit FW, Varani J, Kreutzer DL, Senior RM, Ward PA (1979) Digestion of the fifth component of complement by leukocyte enzymes: Sequential generation of chemotactic activities for leukocytes and for tumor cells. Am J Pathol 94: 75Google Scholar
  128. 128.
    Qsterud B, Lindahl V, Seljelid R (1980) Macrophages produce blood coagulation factors. FEBS Lett 120: 41Google Scholar
  129. 129.
    Qsterud B, Bogwald J, Lindahl U, Seljelid R (1981) Production of blood coagulation Factor V and tissue thromboplastin by macrophages in vitro. FEBS Lett 127: 154Google Scholar
  130. 130.
    Pfueller SL, Luscher EF (1972) The effects of aggregated immunoglobulins on human blood platelets in relation to their complement-fixing abilities J Immunol 109: 517PubMedGoogle Scholar
  131. 131.
    Pfueller SL, Luscher EF (1974) Studies of the mechanisms of human platelet release reaction induced by immunologic stimuli. I. Complement-dependent and complement-independent reactions. J Immunol 112: 1201PubMedGoogle Scholar
  132. 132.
    Pfueller SL, Luscher EF (1974) Studies of the mechanisms of the human platelet release reaction induced by immunologic stimuli. II. The effect of zymosan. J Immunol 112: 1211PubMedGoogle Scholar
  133. 133.
    Pillemer L, Ratnoff OD, Bluf L, Lepow IH (1953) The inactivation of complement and its components by plasmin. J Exp Med 97: 573PubMedGoogle Scholar
  134. 134.
    Plow EF (1982) Leukocyte elastase release during blood coagulation. A potential mechanism for activation of the alternative fibrinolytic pathway. J Clin Invest 69: 564PubMedGoogle Scholar
  135. 135.
    Plow EF, Edgington TS (1975) An alternative pathway for fibrinolysis. I. The cleavage of fibrinogen by leukocyte proteases at physiologic pH. J Clin Invest 56: 30PubMedGoogle Scholar
  136. 136.
    Podack ER, Müller-Eberhard HJ (1980) Limited proteolysis of C5b-6: Functional stability of the degraded complex. J Immunol 124: 332PubMedGoogle Scholar
  137. 137.
    Polley MJ, Nachmann RL (1975) Ultrastructural lesions on the surface of platelets associated with either blood coagulation or with antibody-mediated immune injury. J Exp Med 141: 1261PubMedGoogle Scholar
  138. 138.
    Polley MJ, Nachman RL (1978) The human complement system in thrombin-mediated platelet function. J Exp Med 147: 1713PubMedGoogle Scholar
  139. 139.
    Polley MJ, Nachman RL (1979) Human complement in thrombin-mediated platelet function: Uptake of the C5b-9 complex. J Exp Med 150: 633PubMedGoogle Scholar
  140. 140.
    Polley MJ, Nachman RL, Weksler BB (1981) Human complement in the arachidonic acid transformation pathway in platelets. J Exp Med 153: 257PubMedGoogle Scholar
  141. 141.
    Prydz H, Allison AC, Schorlemmer HU (1977) Further link between complement activation and blood coagulation. Nature 270: 173PubMedGoogle Scholar
  142. 142.
    Prydz H, Lyberg T, Deteix P, Allison AC (1979) In vitro stimulation of tissue thromboplastin ( Factor III) activity in human monocytes by immune complexes and lectins. Thromb Res 15: 465PubMedGoogle Scholar
  143. 143.
    Rapaport SI, Hjort PF (1967) The blood clotting properties of rabbit peritoneal leukocytes in vitro. Thromb Diath Haemorrh 17: 222PubMedGoogle Scholar
  144. 144.
    Ratnoff OD (1969) Some relationships among hemostasis, fibrinolytic phenomena, immunity, and the inflammatory response. Adv Immunol 10: 145PubMedGoogle Scholar
  145. 145.
    Ratnoff OD, Naff GB (1967) The conversion of Cls to Cl esterase by plasmin and trypsin. J Exp Med 125: 337PubMedGoogle Scholar
  146. 146.
    Ratnoff OD, Pensky J, Ogston D, Naff GB (1969) The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the Clr subcomponent of the first component of complement by serum C’1 esterase inhibitor. J Exp Med 129: 315PubMedGoogle Scholar
  147. 147.
    Reid KBM, Porter RR (1981) The proteolytic activation systems of complement. Annu Rev Biochem 50: 433PubMedGoogle Scholar
  148. 148.
    Rickles FR, Hardin JA, Pitlick FA, Hoyer LW, Conrad ME (1973) Tissue factor activity in lymphocyte cultures from normal individuals and patients with hemophilia A. J Clin Invest 52: 1427PubMedGoogle Scholar
  149. 149.
    Rickles FR, Levin J, Hardin JA, Barr CF, Conrad ME (1977) Tissue factor generation by human mononuclear cells: Effects of endotoxin and disassociation of tissue factor generation from mitogenic response. J Lab Clin Med 89: 792PubMedGoogle Scholar
  150. 150.
    Rijken DC, Collen D (1980) Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 256: 7035Google Scholar
  151. 151.
    Rijken DC, Winjngaards G, Zaal-de Jong M, Welbergen J (1979) Purification and partial characterization of plasminogen activator from human uterine tissue. Biochim Biophys Acta 580: 140PubMedGoogle Scholar
  152. 152.
    Rijken DC, Winjngaards G, Welbergen J (1981) Immunological characterization of plasminogen activator activities in human tissues and body fluids. J Lab Clin Med 97: 477PubMedGoogle Scholar
  153. 153.
    Rijken DC, Hoylaerts M, Collen D (1982) Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activators. J Biol Chem 257: 2920PubMedGoogle Scholar
  154. 154.
    Robbins J, Stetson CA (1959) An effect of antigen-antibody interaction on blood coagulation. J Exp Med 109: 1PubMedGoogle Scholar
  155. 155.
    Rodriguez-Erdmann F (1964) Studies on the pathogenesis of the generalized Shwartzman reaction. I. Alterations in the coagulation system during the generalized Shwartzman reaction of the pregnant rabbit. Thromb Diath Haemorrh 12: 452PubMedGoogle Scholar
  156. 156.
    Rodriguez-Erdmann F (1964) Studies on the pathogenesis of the generalized Shwartzman reaction. II. Role played by experimentally induced fibrinolysis. Thromb Diath Haemorrh 12: 462PubMedGoogle Scholar
  157. 157.
    Rosing J, Tans G, Govers-Riemslag JWP, Zwaal RFA, Hemker HC (1980) The role of phospholipids and Factor Va in the prothrombinase complex. J Biol Chem 255: 274PubMedGoogle Scholar
  158. 158.
    Ross GD (1982) Structure and function of membrane complement receptors. Fed Proc 41: 3089PubMedGoogle Scholar
  159. 159.
    Rothberger H, Zimmerman TS, Spiegelberg HL, Vaughan JH (1977) Leukocyte procoagulant activity: Enhancement of production in vitro by IgG and antigen-antibody complexes. J Clin Invest 59: 549PubMedGoogle Scholar
  160. 160.
    Salzman EW (1972) Cyclic AMP and platelet function. N Engl J Med 286: 358PubMedGoogle Scholar
  161. 161.
    Schorlemmer HU, Bitter-Suermann D, Allison AC (1977) Complement activation by the alternative pathway and macrophage enzyme secretion in the pathogenesis of chronic inflammation. Immunology 32: 929PubMedGoogle Scholar
  162. 162.
    Schreiber AD, Kaplan AP, Austen KF (1973) Inhibition by Cl INH of Hageman factor fragment activation of coagulation, fibrinolysis, and kinin generation. J Clin Invest 52: 1402PubMedGoogle Scholar
  163. 163.
    Schreiber AD, Kaplan AP, Austen KF (1973) Plasma inhibitors of the components of the fibrinolytic pathway in man. J Clin Invest 52: 1394PubMedGoogle Scholar
  164. 164.
    Schwartz BS, Edgington TS (1981) Immune complex-induced human monocyte procoagulant activity. I. A rapid unidirectional lymphocyte instructed pathway. J Exp Med 154: 892PubMedGoogle Scholar
  165. 165.
    Schwartz BS, Levy GA, Curtiss LK, Fair DS, Edgington TS (1981) Plasma lipoprotein induction and suppression of the generation of cellular procoagulant activity in vitro. Two procoagulant activities are produced by peripheral blood mononuclear cells. J Clin Invest 67: 1650PubMedGoogle Scholar
  166. 166.
    Shaw JO, Pinckard RN, Ferrigni KS, McManus LM, Hanahan DJ (1981) Activation of human neutrophils with 1-o-hexadecyl/octadecyl-2-acetyl-Sn-glycerol-3-phosphate (platelet-activating factor). J Immunol 127: 1250PubMedGoogle Scholar
  167. 167.
    Siraganian RP (1972) Platelet requirement in the interaction of complement and clotting systems. Nature 239: 208Google Scholar
  168. 168.
    Stetson CA (1951) The occurrence of leucocyte-platelet thrombosis in rheumatic carditis. J Exp Med 94: 493PubMedGoogle Scholar
  169. 169.
    Suba EA, Scako G (1976) Clq (C1) receptor on human platelets: Inhibition of collagen-induced platelet aggregation by Clq (cl) molecules. J Immunol 117: 304PubMedGoogle Scholar
  170. 170.
    Sumi H, Muramatu M, Jugii S (1973) The relation of C ls, a subunit of the activated first component of complement, to other plasma enzymes. Biochim Biophys Acta 327: 207PubMedGoogle Scholar
  171. 171.
    Sundsmo JS (1980) Expression of complement on human peripheral blood lymphocytes. Fed Proc 39: 1200Google Scholar
  172. 172.
    Sundsmo JS (1982) The leukocyte complement system. Fed Proc 41: 3094PubMedGoogle Scholar
  173. 173.
    Sundsmo JS, Fair DS (to be published) Leukocyte complement: A possible role for complement and Factor B in lymphocyte stimulation.Google Scholar
  174. 174.
    Sundsmo JS, Wood LM (1981) Activated Factor B (Bb) of the alternative pathway of complement cleaves and activates plasminogen. J Immunol 127: 877PubMedGoogle Scholar
  175. 175.
    Sundsmo JS, Curd JG, Kolb WP, Müller-Eberhard HJ (1978) Leukocyte complement: Assembly of the membrane attack complex of complement by human peripheral blood leukocytes in the presence and absence of serum. J Immunol 120: 855PubMedGoogle Scholar
  176. 176.
    Tack BF, Morris SC, Prahl JW (1979) Third component of human complement: Structural analysis of the polypeptide chains of C3 and C3b. Biochemistry 18: 1497PubMedGoogle Scholar
  177. 177.
    Tans G, Griffin JH (1982) Properties of sulfatides in Factor XII-dependent contact activation. Blood 59: 69PubMedGoogle Scholar
  178. 178.
    Taubman SB, Lepow IH (1971) Cleavage of human Cl s by human lysosomal enzymes, plasmin, and trypsin. Immunochemistry 8: 951PubMedGoogle Scholar
  179. 179.
    Taylor FB, Müller-Eberhard HJ (1968) A qualitative description of factors involved in lysis of dilute whole blood clots. J Immunol 101: 820Google Scholar
  180. 180.
    Taylor FB, Müller-Eberhard HJ (1970) Qualitative description of factors involved in the retraction and lysis of dilute whole blood clots and in aggregation and retraction of platelets. J Clin Invest 49: 2068PubMedGoogle Scholar
  181. 181.
    Taylor FB, Ward PA (1967) Generation of chemotactic activity in rabbit serum by plasminogen-streptokinase mixtures. J Exp Med 26: 149Google Scholar
  182. 182.
    Taylor JC, Crawford IP, Hugli TE (1977) Limited degradation of the third component (C3) of human complement by human leukocyte elastase (HLE): Partial characterization of C3 fragments. Biochemistry 16: 3390PubMedGoogle Scholar
  183. 183.
    Tenner AJ, Cooper NR (1980) Analysis of receptor-mediated Clq binding to human peripheral blood mononuclear cells. J Immunol 125: 1658PubMedGoogle Scholar
  184. 184.
    Thomas M, Good RA (1952) Studies on the generalized Shwartzman reaction. I. General observations concerning the phenomenon. J Exp Med 96: 605PubMedGoogle Scholar
  185. 185.
    Thompson RA, Rowe DS (1968) Reactive haemolysis — A distinct form of red cell lysis. Immunology 14: 745PubMedGoogle Scholar
  186. 186.
    Tomikawa M, Abiko Y (1973) The plasminogen-plasmin system. Part VIII. On the mechanism of chemical induction of fibrinolysis. Isolation of a latent plasminogen activator from human plasma. Thromb Diath Haemorrh 29: 50PubMedGoogle Scholar
  187. 187.
    Tsao B, Fair DS Curtiss LK, Edgington TS (to be published) Expression of Factor VII activity in lipopolysaccharide stimulated human peripheral mononuclear cells. BloodGoogle Scholar
  188. 188.
    Ulevitch RJ, Cochrane CG, Henson PM, Morrison DC, Doe WF (1975) Mediation systems in bacterial lipopolysaccharide-induced hypotension and disseminated intravascular coagulation. I. The role of complement. J Exp Med 142: 1570PubMedGoogle Scholar
  189. 189.
    Unkeless JD, Gordon S, Reich E (1974) Secretion of plasminogen activator by stimulated macrophages. J Exp Med 139: 834PubMedGoogle Scholar
  190. 190.
    van Ginkel CJW, van Aken WG (1980) Generation of tissue thromboplastin by human monocytes. In: van Furth R (ed) Mononuclear phagocytes: Functional aspects. Martinus Nijhoff Publishers, The Hague, p 1351Google Scholar
  191. 191.
    Vassali P, McCluskey RT (1976) The pathogenic role of coagulation process in glomerular diseases of immunologic origin. Adv Nephrol 1: 47Google Scholar
  192. 192.
    Venerrod AM, Laake K (1976) Prekallikrein and plasminogen proactivator: Absence of plasminogen proactivator in Fletcher factor deficient plasma. Thromb Res 8: 519Google Scholar
  193. 193.
    Venge P, Olsson I (1975) Cationic protein of human granulocytes. VI. Effects on the complement system and mediation of chemotactic activity. J Immunol 115: 1505PubMedGoogle Scholar
  194. 194.
    Wallen P, Kok P, Ranby M (1978) The tissue activator of plasminogen. In: Magnusson S, Ottegen M, Foltman B, Dano K, Neurath H (eds) Regulatory enzymes and their controls. Pergammon Press, Oxford, p 127Google Scholar
  195. 195.
    Ward PA (1967) A plasmin-split fragment of C3 as a new chemotactic factor. J Exp Med 126: 189PubMedGoogle Scholar
  196. 196.
    Ward PA, Cochrane CG, Müller-Eberhard HJ (1965) The role of serum complement in chemotaxis of PMN’s. J Exp Med 122: 327PubMedGoogle Scholar
  197. 197.
    Wautier JL, Tobelem GM, Peltier AP, Caen JP (1974) Evidence for Cl on human platelets. Haemostasis 2: 281Google Scholar
  198. 198.
    Wautier JL, Tobelem GM, Peltier AP, Caen JP (1976) Cl and human platelets. II. Detection by immunological methods and role. Immunology 30: 459PubMedGoogle Scholar
  199. 199.
    Wautier JL, Sonchon H, Cohen-Solal L, Peltier AP, Caen JP (1976) Cl and human platelets. III. Role of Cl subcomponent in platelet aggregation induced by aggregated IgG. Immunology 31: 595PubMedGoogle Scholar
  200. 200.
    Wautier JL, Souchon H, Reid KBM, Peltier AP, Caen JP (1977) Studies on the mode of reaction of the first component of complement with platelets: Interaction between collagen-like portion of C 1 q and platelets. Immunochemistry 14: 763PubMedGoogle Scholar
  201. 201.
    Wautier JL, Reid KBM, Legrand Y, Caen JP (1980) Region of the Clq molecule involved in the interaction between platelets and the subcomponent Clq of the first component of complement. Mol Immunol 17: 1399PubMedGoogle Scholar
  202. 202.
    Wautier JL, Ollier-Hartmann MP, Kadeva H, Cohen F, Hartmann L, Caen JP (1981) First component of complement and thrombosis. Thromb Haemost 45: 247PubMedGoogle Scholar
  203. 203.
    Webster RO, Hong SR, Johnston RB, Henson PM (1980) Biological effects of the human complement fragments C5a and C5a desarg on neutrophil function. Immunopharmacology 2: 201PubMedGoogle Scholar
  204. 204.
    Webster RO, Zanolari B, Henson PM (1980) Neutrophil chemotaxis in response to surface bound human C5a. Exp Cell Res 129: 55PubMedGoogle Scholar
  205. 205.
    Weigle WO, Morgan EL, Goodman MG, Chenoweth DE, Hugh TE (1982) Modulation of the immune response by anaphylatoxin in the microenvironment of the interacting cells. Fed Proc 41: 3099PubMedGoogle Scholar
  206. 206.
    Weissmann G, Samuelsson B, Paoletti R, Eds (1979) Advances in inflammation research. Raven Press, New YorkGoogle Scholar
  207. 207.
    Weksler BB, Coupal CE (1973) Platelet-dependent generation of chemotactic activity in serum. J Exp Med 137: 1419PubMedGoogle Scholar
  208. 208.
    Wiggins RC, Giclas PC, Henson PM (1981) Chemotactic activity generated from the fifth component of complement by plasma kallikrein of rabbit. J Exp Med 153: 1391PubMedGoogle Scholar
  209. 209.
    Wiman B, Collen D (1978) Molecular mechanism of physiological fibrinolysis. Nature 272: 549PubMedGoogle Scholar
  210. 210.
    Woolridge D, Spragg J, Austen KF (1974) Interaction of Hageman factor-dependent systems with the complement sequence. In: Pisano JJ, Austen KF (eds) Chemistry and biology of the kallikreinkinin systems in health and disease. National Institute of Health Monograph, Bethesda, p 221Google Scholar
  211. 211.
    Wright PG, Gallin JJ (1977) A functional differentiation of human neutrophil granules: Generation of C5a by a specific (secondary) granule product and inactivation of C5a by azurophil (primary) granule products. J Immunol 119: 1068PubMedGoogle Scholar
  212. 212.
    Wuepper KD (1972) Biochemistry and biology of components of the plasma kinin-forming system. In: Lepow IH, Ward PA (eds) Inflammation mechanisms and control. Academic Press, New York, p 93Google Scholar
  213. 213.
    Ziccardi RJ (1982) Spontaneous activation of the first component of human complement (C 1) by an intramolecular autocatalytic mechanism. J Immunol 128: 2500PubMedGoogle Scholar
  214. 214.
    Ziccardi RJ (1982) A new role of C1-inhibitor in homeostasis: Control of activation of the first component of human complement. J Immunol 128: 2505PubMedGoogle Scholar
  215. 215.
    Zimmerman TS (1976) The coagulation mechanism and the inflammatory response. In: Miescher PA, Müller-Eberhard HJ (eds) Textbook of immunopathology. Grune and Stratton, New York, p 95Google Scholar
  216. 216.
    Zimmerman TS, Kolb WP (1976) Human platelet-initiated formation and uptake of the C5–9 complex of human complement. J Clin Invest 57: 203PubMedGoogle Scholar
  217. 217.
    Zimmerman TS, Müller-Eberhard HJ (1971) Blood coagulation initiation by complement-mediated pathway. J Exp Med 134: 1601PubMedGoogle Scholar
  218. 218.
    Zimmerman TS, Arroyave CM, Müller-Eberhard HJ (1971) A blood coagulation abnormality in rabbits deficient in the sixth component of complement (C6) and its correction by purified C6. J Exp Med 134: 1591PubMedGoogle Scholar
  219. 219.
    Zimmerman TS, Fierer J, Rothberger H (1977) Blood coagulation and the inflammatory response. Semin Hematol 14: 391PubMedGoogle Scholar
  220. 220.
    Zucker MB, Grant RA (1974) Aggregation and release reaction induced in human blood by zymosan. J Immunol 112: 1219PubMedGoogle Scholar
  221. 221.
    Zucker MB, Grant RA, Alper CA, Goodkofsky I, Lepow IH (1974) Requirement for complement components and fibrinogen in the zymosan-induced release reaction of human blood platelets. J Immunol 113: 1744PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • John S. Sundsmo
    • 1
  • Daryl S. Fair
    • 1
  1. 1.Department of ImmunologyResearch Institute of Scripps ClinicLa JollaUSA

Personalised recommendations